Physician profile
Roland Goode
NPI 1972765428
$872.55
in general payments reported to CMS, 2019-2025
12 companies · $35.83 in 2025
The $35.83 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.75 · 2020: $71.19 · 2021: $327 · 2022: $93.86 · 2023: $70.15 · 2024: $247 · 2025: $35.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $312.83 | 2019-2025 | Advantage System, Lithovue |
| Abbvie INC. | $181.93 | 2021-2025 | |
| Allergan, INC. | $79.13 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $56.09 | 2020-2022 | |
| Procept Biorobotics Corporation | $52.87 | 2020 | |
| Astellas Pharma US INC | $51.99 | 2021 | |
| Urogen Pharma, INC. | $48.06 | 2021-2022 | |
| Ambu INC. | $30.27 | 2021 | |
| Accord Healthcare, INC. | $20.82 | 2024 | |
| Progenics Pharmaceuticals, INC. | $20.18 | 2023 | Pylarify |
| Endo USA, INC. | $13.07 | 2024 | Xiaflex |
| Travere Therapeutics, INC. | $5.31 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roland Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.